China's CanSino defends Covid-19 vaccine candidate after experts cast doubt

China's CanSino Biologics Inc said on Wednesday expert opinion on its high-profile coronavirus vaccine candidate should not be followed "blindly" without sufficient clinical trial data.

For latest updates and live news on coronavirus, click here

Scientists outside the company have expressed concern that the effectiveness of CanSino's candidate Ad5-nCoV, which is based on a common cold virus that many people have been exposed to, could be limited. They said existing antibodies against the common cold virus might undermine Ad5-nCoV.

Coronavirus vaccine news live updates on DH

"Vaccine development is a practice-based science, and we should not blindly follow experts," Zhu Tao, chief scientific officer, said during an investor conference.

Ad5-nCoV, still in final-stage trials, has been approved for use in the Chinese military.